Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer

Detalles Bibliográficos
Autores principales: Molto Valiente, Consolacion, Amir, Eitan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Editorial Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425633/
https://www.ncbi.nlm.nih.gov/pubmed/37588734
http://dx.doi.org/10.21037/tcr-23-365
_version_ 1785089878869934080
author Molto Valiente, Consolacion
Amir, Eitan
author_facet Molto Valiente, Consolacion
Amir, Eitan
author_sort Molto Valiente, Consolacion
collection PubMed
description
format Online
Article
Text
id pubmed-10425633
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-104256332023-08-16 Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer Molto Valiente, Consolacion Amir, Eitan Transl Cancer Res Editorial Commentary AME Publishing Company 2023-07-03 2023-07-31 /pmc/articles/PMC10425633/ /pubmed/37588734 http://dx.doi.org/10.21037/tcr-23-365 Text en 2023 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Editorial Commentary
Molto Valiente, Consolacion
Amir, Eitan
Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer
title Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer
title_full Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer
title_fullStr Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer
title_full_unstemmed Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer
title_short Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer
title_sort combining parp inhibitors and platinum-based chemotherapy in metastatic triple negative and/or brca-associated breast cancer
topic Editorial Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425633/
https://www.ncbi.nlm.nih.gov/pubmed/37588734
http://dx.doi.org/10.21037/tcr-23-365
work_keys_str_mv AT moltovalienteconsolacion combiningparpinhibitorsandplatinumbasedchemotherapyinmetastatictriplenegativeandorbrcaassociatedbreastcancer
AT amireitan combiningparpinhibitorsandplatinumbasedchemotherapyinmetastatictriplenegativeandorbrcaassociatedbreastcancer

Ejemplares similares